The Asan Medical Center's (AMC) Clinical Trial Center in South Korea has signed a memorandum of understanding with Asia Pacific specialist CRO Novotech.
The MOU formalizes Novotech's relationship with the South Korea’s largest medical institution and its principal investigators.
Under the terms of the MOU, the AMC will provide professional and medical advice to Novotech for clinical trials conducted in AMC, including feasibility, principal investigator selection and assistance with patient recruitment.
Novotech will help in promoting the clinical research capabilities of the AMC internationally. Both parties have agreed to continue expanding the future scope of the collaboration.
"AMC has been very successful in delivering and supporting many complicated clinical trials, including early phase clinical trials,” said Young Suk Lim, director of AMC Clinical Trial Center. “Based on the MOU, the AMC is committed to increasing and expanding its global-level of medical and technological infrastructure, and continuing to deliver quality clinical trial support."
Novotech CEO John Moller said they have worked closely with the AMC's Clinical Trial Center on many clinical trials over the past 10 years of presence in South Korea.
"AMC's size, high-quality facilities and technological infrastructure are crucial in delivering speedy patient recruitment, quality clinical trial management and robust trial data. AMC has over 2,700 beds and the volume of available patients is huge by Western standards,” said Moller.
“Other elements which contribute to South Korea being a leading destination for clinical trials include its efficient regulatory environment and its high standards of trial conduct," he added.